WINTON GROUP Ltd Invests $1.79 Million in Biogen Inc. $BIIB

WINTON GROUP Ltd bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,145 shares of the biotechnology company’s stock, valued at approximately $1,785,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Rothschild Investment LLC lifted its position in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares during the last quarter. Advisory Services Network LLC raised its holdings in shares of Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares in the last quarter. Davis Investment Partners LLC raised its holdings in shares of Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares in the last quarter. Optas LLC raised its holdings in shares of Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 73 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Biogen by 1.9% in the fourth quarter. Parallel Advisors LLC now owns 4,302 shares of the biotechnology company’s stock valued at $757,000 after acquiring an additional 79 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB’s Next-Gen SMA Therapy Salanersen Wins FDA’s Breakthrough Tag
• Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long?Term Growth
• Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
• Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
• Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Biogen Price Performance

BIIB opened at $195.34 on Monday. The business’s 50-day moving average is $187.60 and its two-hundred day moving average is $183.46. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm has a market capitalization of $28.84 billion, a PE ratio of 20.96 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the firm earned $3.02 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Research analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BIIB shares. HC Wainwright restated a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Wedbush lifted their price objective on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a report on Thursday, April 30th. Rothschild & Co Redburn lifted their price objective on Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. Argus upgraded Biogen to a “hold” rating in a report on Thursday, April 9th. Finally, UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $215.81.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.